2. Metabolic Enzyme/Protease MAPK/ERK Pathway Stem Cell/Wnt
  3. Dipeptidyl Peptidase p38 MAPK ERK
  4. YS110

YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS.

For research use only. We do not sell to patients.

YS110 Chemical Structure

YS110 Chemical Structure

CAS No. : 1656248-21-3

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

YS110 Related Antibodies

Top Publications Citing Use of Products

View All Dipeptidyl Peptidase Isoform Specific Products:

View All Isoforms
DPP-1 DPP-2 DPP-4 DPP-8 DPP-9

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
IC50 & Target[1]

p38 MAPK

 

DPP-4

 

In Vitro

YS110 (0-250 μg/mL, 48 h) inhibits cell proliferation in a concentration dependent manner in NCI-H2452 cells[1].
YS110 (2 μg/mL, 24 h) leads to a significant increase in the proportion of G2/M phase and affects the expression of related proteins in NCI-H2452 cells[1].
YS110 (2 μg/mL, 6-24 h) elevates activating phosphorylation of p38 MAPK and ERK1/2 in NCI-H2452 cells[1].
YS110 (0-20 μg/mL, 48 h) inhibits cell growth of JMN cells in a dose-dependent manner[2].
YS110 (0-4 h) relies on the caveolin pathway to induce CD26 nuclear translocation in JMN cells[2].
YS110 (2 μg/mL, 3 h) significantly inhibits the mRNA and protein levels of POLR2A in JMN cells [2].
YS110 (10 μg/mL, 30 min) effectively inhibits MERS CoV S1-Fc specific binding to CD26 in JKT-hCD26WT cells[3].
YS110 (40 μg/mL, 30 min) significantly reduces MERS CoV infection rate in Huh-7 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

YS110 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: NCI-H2452 cells
Concentration: 0, 0.1, 2, 10 and 250 μg/mL
Incubation Time: 48 h
Result: Inhibited the cell proliferation of NCI-H2452 cells.

Cell Cycle Analysis[1]

Cell Line: NCI-H2452 cells
Concentration: 2 μg/mL
Incubation Time: 24 h
Result: Significantly increased the proportion of G2/M phase cells with an average increase of 8 %.

Western Blot Analysis[1]

Cell Line: NCI-H2452 cells
Concentration: 2 μg/mL
Incubation Time: 6 and 24 h
Result: Significantly increased the level of p21, p-cdc2, p-cdc25C, p-p38 MAPK and p-ERK1/2.

RT-PCR[2]

Cell Line: JMN cells
Concentration: 2 μg/mL
Incubation Time: 3 h
Result: Significantly reduced the mRNA level of POLR2A.

Western Blot Analysis[2]

Cell Line: JMN cells
Concentration: 2 μg/mL
Incubation Time: 3 h
Result: Significantly reduced the protein level of POLR2A.
In Vivo

YS110 (5 mg/kg or 5 μg, intratumoral injection or i.p., three times per week) can significantly inhibit tumor growth in NOG mice bearing JMN xenograft[1].
YS110 (8 mg/kg or 10 μg, intratumoral injection or i.p., three times per week) significantly inhibits tumor volume and weight in NOG mice bearing JMN or MSTO/clone12 (MSTO/CD26) cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/Shi-scid, IL-2 receptor gamma null (NOG) mice bearing 1×106 JMN cells[1]
Dosage: 5 mg/kg or 5 μg
Administration: Intratumoral injection of 5 mg/kg; Intraperitoneal injection (i.p.) of 5μg, combinated with Pemetrexed (HY-10820) (100 mg/kg)
Result: Significantly inhibited tumor growth, reduced Ki-67 positive cells, and increased necrotic areas.
Animal Model: NOD/Shi-scid, IL-2 receptor gamma null (NOG) mice bearing 1×106 JMN cells or MSTO/clone12 (MSTO/CD26) cells[2]
Dosage: 8 mg/kg or 10 μg
Administration: Intratumoral injection of 8 mg/kg; Intraperitoneal injection (i.p.) of 10 μg
Result: Significantly inhibited tumor volume and weight, and reduced POLR2A protein levels in tumors.
Gene ID

1803  [NCBI]

Accession
Target

DPP4/CD26
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
CAS No.
SMILES

N/A
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

YS110 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

YS1101656248-21-3YS 110YS-110Dipeptidyl Peptidasep38 MAPKERKDPPExtracellular signal regulated kinasesCD26p38MAPKMesotheliomacancerMERSInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
YS110
Cat. No.:
HY-P991551
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.